Wohler Laboratories Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 16-12-2024
- Company Age 19 Year, 8 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.75 Cr
as on 16-12-2024
- Revenue -100.00%
(FY 2023)
- Profit -117.57%
(FY 2023)
- Ebitda -210.17%
(FY 2023)
- Net Worth -26.33%
(FY 2023)
- Total Assets -6.38%
(FY 2023)
About Wohler Laboratories
The Corporate was formerly known as Wohler Chemicals And Intermediaries Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹5.75 Cr.
Gaddam Ramana and Gaddam Rao serve as directors at the Company.
- CIN/LLPIN
U24110TG2005PTC048439
- Company No.
048439
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Dec 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Wohler Laboratories Private Limited offer?
Wohler Laboratories Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Lithium Compound, Chemical Reagents & Catalysts, Laboratory Reagents, Bromine Compound, Cis Bromo Benzoate.
Who are the key members and board of directors at Wohler Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaddam Ramana  | Director | 01-Sep-2018 | Current |
| Gaddam Rao | Director | 22-Aug-2018 | Current |
Financial Performance of Wohler Laboratories.
Wohler Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 117.57% decrease in profit. The company's net worth observed a substantial decline by a decrease of 26.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wohler Laboratories?
In 2023, Wohler Laboratories had a public holding of 74.77%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 09 Aug 2010 | ₹5.75 Cr | Open |
How Many Employees Work at Wohler Laboratories?
Unlock and access historical data on people associated with Wohler Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wohler Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wohler Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
